Literature DB >> 7511248

Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression.

M Maes1, S Scharpé, H Y Meltzer, E Bosmans, E Suy, J Calabrese, P Cosyns.   

Abstract

Recent studies from this laboratory have provided some evidence that major depression, in particular melancholia, may be accompanied by an immune response. The present study was designed to investigate whether severe depression is characterized by increased interleukin-6 (Il-6) activity and whether Il-6 production is related to altered levels of acute phase reactants and to abnormal function of the hypothalamic-pituitary-adrenal (HPA) axis. Measurements were made in 8 healthy control subjects and 24 depressed inpatients of Il-6 production in culture supernatants of mitogen-stimulated peripheral leukocytes and plasma levels of haptoglobin (Hp), transferrin (Tf), and postdexamethasone cortisol. Il-6 activity was significantly higher in melancholic subjects than in healthy control subjects and in patients with minor depression or nonmelancholic major depression. Il-6 production was significantly correlated with Hp (positively) and Tf (negatively) plasma levels. There were significant and positive correlations between Il-6 activity and postdexamethasone cortisol values. The findings may suggest that increased Il-6 activity in severe depression is related to hypotransferrinemia, hyperhaptoglobinemia, and hyperactivity of the HPA axis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7511248     DOI: 10.1016/0165-1781(93)90027-e

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  75 in total

Review 1.  Known and potential roles of transferrin in iron biology.

Authors:  Thomas Benedict Bartnikas
Journal:  Biometals       Date:  2012-08       Impact factor: 2.949

Review 2.  Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions.

Authors:  Kristen Farrell; Michael H Antoni
Journal:  Fertil Steril       Date:  2010-05-14       Impact factor: 7.329

Review 3.  Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications.

Authors:  George Anderson; Michael Berk; Olivia Dean; Steven Moylan; Michael Maes
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 4.  Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies.

Authors:  Jennifer M Loftis; Marilyn Huckans; Benjamin J Morasco
Journal:  Neurobiol Dis       Date:  2009-11-26       Impact factor: 5.996

Review 5.  Immune system to brain signaling: neuropsychopharmacological implications.

Authors:  Lucile Capuron; Andrew H Miller
Journal:  Pharmacol Ther       Date:  2011-02-17       Impact factor: 12.310

Review 6.  Immunoglobulin-mediated neuro-cognitive impairment: new data and a comprehensive review.

Authors:  Assaf Menachem; Joab Chapman; Yael Deri; Chaim G Pick; Aviva Katzav
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

Review 7.  Severe depression: is there a best approach?

Authors:  S B Sonawalla; M Fava
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

8.  Beta adrenergic blockade decreases the immunomodulatory effects of social disruption stress.

Authors:  M L Hanke; N D Powell; L M Stiner; M T Bailey; J F Sheridan
Journal:  Brain Behav Immun       Date:  2012-07-24       Impact factor: 7.217

Review 9.  Interleukin 18 in the CNS.

Authors:  Silvia Alboni; Davide Cervia; Shuei Sugama; Bruno Conti
Journal:  J Neuroinflammation       Date:  2010-01-29       Impact factor: 8.322

10.  Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization.

Authors:  Samantha E Yohn; Yumna Arif; Allison Haley; Guiseppe Tripodi; Younis Baqi; Christa E Müller; Noemi San Miguel; Mercè Correa; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2016-08-06       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.